

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

*Gedulin et al.*

Appl. No.: 10/518,128

371(c) Filing Date: August 29, 2005

For: Prevention and/or Treatment of  
Inflammatory Bowel Disease Using  
PYY or Agonists Thereof

Confirmation No.: 7370

Art Unit: 1646

Examiner: Li, Ruixiang

Atty. Docket: 0402US-UTL

**Amendment and Response under 37 C.F.R. § 1.111**

Mail Stop – Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is a Response to the final Office Action dated September 2, 2009, in connection with the above-identified application. A Request for Continued Examination (RCE), a supplemental Information Disclosure Statement (sIDS), and authorization to charge the requisite fees accompany this Response. Accordingly, this Response, the RCE, and the sIDS are timely filed.

Applicants have given careful consideration to the grounds for rejection and objection. The following amendments and remarks are believed to place this application in condition for allowance, which is respectfully requested.

**Amendments to the claims** begin on page 2 of this paper

**Remarks** begin on page 6 of this paper.

**An Exhibit** begins on page 12 of this paper